UKPDS Publications

Latest (2020- )

brief history of the UK Prospective Diabetes Study

Holman RR., (2022), BRITISH JOURNAL OF DIABETES, 22, S32 - S35

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).

Leal J. et al, (2021), Diabet Med, 38

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.

Lind M. et al, (2021), Diabetes Care, 44, 2231 - 2237

Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.

Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884

Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).

Agbaje OF. et al, (2020), Diabetes Res Clin Pract, 166

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).

Maddaloni E. et al, (2020), Lancet Diabetes Endocrinol, 8, 206 - 215

2010-2019

Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E. et al, (2019), Diabetes Obes Metab, 21, 2115 - 2122

Health selection into neighborhoods among patients enrolled in a clinical trial.

Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54

Microvascular outcomes in type 2 diabetes - Authors' reply.

Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5, 431 - 437

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).

Alva ML. et al, (2015), Diabet Med, 32, 459 - 466

Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort: does the ADDITION validation add up?

Gray A. et al, (2014), Value Health, 17, 895 - 896

Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)

Davis TME. et al, (2014), Diabetic Medicine, 31, 200 - 207

UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

Hayes AJ. et al, (2013), Diabetologia, 56, 1925 - 1933

Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.

Leal J. et al, (2013), Diabetes Care, 36, 1541 - 1546

Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.

Davis TME. et al, (2013), Circulation, 127, 980 - 987

2001

The UKPDS: implications for the dyslipidaemic patient.

Holman R., (2001), Acta Diabetol, 38 Suppl 1, S9 - 14

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

Stevens RJ. et al, (2001), Clin Sci (Lond), 101, 671 - 679

Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679))

Stevens RI. et al, (2002), Clinical Science, 102

Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.

Clarke R. et al, (2001), J Cardiovasc Risk, 8, 363 - 369

Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.

Hashim Y. et al, (2001), Diabetologia, 44, 2227 - 2230

n economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).

Gray A. et al, (2001), Diabet Med, 18, 438 - 444

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).

Kohner EM. et al, (2001), Diabet Med, 18, 178 - 184

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Clarke P. et al, (2001), Diabetologia, 44, 298 - 304

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.

Stratton IM. et al, (2001), Diabetologia, 44, 156 - 163

2000

Life-expectancy projection by modelling and computer simulation (UKPDS 46).

Stevens R. et al, (2000), Diabetes Res Clin Pract, 50 Suppl 3, S5 - 13

Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed.

Holman R., (2000), BMJ, 321, 1078 - 1079

ssociation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Adler AI. et al, (2000), BMJ, 321, 412 - 419

ssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Stratton IM. et al, (2000), BMJ, 321, 405 - 412

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)

Manley SE. et al, (2000), Diabetic Medicine, 17, 518 - 523

1999

Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47)

Adler AI. et al, (1999), American Heart Journal, 138, S353 - S359

Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group.

Kohner EM. et al, (1999), Diabetologia, 42, 1107 - 1112

UKPDS: what was the question? UK Prospective Diabetes Study.

Turner R. et al, (1999), Lancet, 354

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

(1999), Diabetes Care, 22, 1125 - 1136

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)

Turner RC. et al, (1999), Journal of the American Medical Association, 281, 2005 - 2012

Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group.

Horton V. et al, (1999), Diabetologia, 42, 608 - 616

1998

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

UK Prospective Diabetes Study Group ., (1998), BMJ, 317, 703 - 713

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

UK Prospective Diabetes Study Group ., (1998), BMJ, 317, 713 - 720

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40

Gray A., (1998), British Medical Journal, 317, 720 - 726

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

Turner R. et al, (1998), Lancet, 352, 837 - 853

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

Turner R. et al, (1998), Lancet, 352, 854 - 865

Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32).

(1998), Diabetes Care, 21, 1271 - 1277

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years

Matthews DR. et al, (1998), Diabetic Medicine, 15, 297 - 303

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).

Turner RC. et al, (1998), BMJ, 316, 823 - 828

United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.

Kohner EM. et al, (1998), Arch Ophthalmol, 116, 297 - 303

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

(1998), Ann Intern Med, 128, 165 - 175

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes

Wright AD. et al, (1998), Diabetes Care, 21, 87 - 92

1997

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.

Turner R. et al, (1997), Lancet, 350, 1288 - 1293

U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex.

(1997), Diabetes Care, 20, 1683 - 1687

U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.

Davis TM. et al, (1997), Diabetes Care, 20, 1435 - 1441

Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.

Turner RC. et al, (1997), Diabetologia, 40 Suppl 2, S121 - S122

UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.

Widjaja A. et al, (1997), J Clin Endocrinol Metab, 82, 654 - 657

1996

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.

(1996), Diabetologia, 39, 1554 - 1561

The UK Prospective Diabetes Study

Turner RC. and Holman RR., (1996), Annals of Medicine, 28, 439 - 444

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy

Eeley EA. et al, (1996), DIABETIC MEDICINE, 13, 656 - 662

U.K. prospective diabetes study.

Tubner RC. et al, (1996), Diabetes Care, 19, 182 - 183

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

Turner R. et al, (1996), Ann Intern Med, 124, 136 - 145

1995

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease

Holman RR., (2016), Diabetes

UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.

Keavney BD. et al, (1995), Diabetologia, 38, 948 - 952

Lessons from UK prospective diabetes study.

Turner RC. and Holman RR., (1995), Diabetes Res Clin Pract, 28 Suppl, S151 - S157

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

(1995), BMJ, 310, 83 - 88

1994

Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.

(1994), Diabet Med, 11, 773 - 782

UK Prospective Diabetes Study. XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. UK Prospective Diabetes Study Group.

(1994), Diabet Med, 11, 670 - 677

UK Prospective Diabetes Study (UKPDS). XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects.

(1994), Diabet Med, 11, 534 - 544

1993

The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results

Levy JC. et al, (1993), Journées annuelles de diabétologie de l'Hôtel-Dieu, 123 - 137

UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia.

(1993), Diabetologia, 36, 1021 - 1029

UK Prospective Diabetes Study (UKPDS). IX: Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy.

(1993), Diabetologia, 36, 835 - 842

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.

(1993), J Hypertens, 11, 309 - 317

Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients.

(1993), J Hypertens, 11, 319 - 325

1991

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

(1991), Diabetologia, 34, 877 - 890

1990

UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group.

(1990), Metabolism, 39, 905 - 912

1988

UK Prospective Diabetes Study. V. Characteristics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet 4-cell function. Multi-centre study.

(1988), Diabet Med, 5, 444 - 448

UK Prospective Diabetes Study. IV. Characteristics of newly presenting type 2 diabetic patients: male preponderance and obesity at different ages. Multi-center Study.

(1988), Diabet Med, 5, 154 - 159

1985

United Kingdom Prospective Diabetes Study. III. Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. A multicenter study.

(1985), Hypertension, 7, II8 - I13

U.K. Prospective Diabetes Study: II. Reduction in HbA1c with Basal Insulin Supplement, Sulfonylurea, or Biguanide Therapy in Maturity-onset Diabetes

(1985), Diabetes, 34, 793 - 798

1983

UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year.

(1983), Diabetologia, 24, 404 - 411

Cookies on this website